Tau immunotherapies: Lessons learned, current status and future considerations.
Tau immunotherapies: Lessons learned, current status and future considerations.
Neuropharmacology. 2020 Apr 28;:108104
Authors: Sandusky-Beltran LA, Sigurdsson EM
Abstract
The majority of clinical trials targeting the tau protein in Alzheimer's disease and other tauopathies are tau immunotherapies. Because tau pathology correlates better with the degree of dementia than amyloid-β lesions, targeting tau is likely to be more effective in improving cognition than clearing amyloid-β in Alzheimer's disease. However, the development of tau therapies is in many ways more complex than for amyloid-β therapies as briefly outlined in this review. Most of the trials are on humanized antibodies, which may have very different properties than the original mouse antibodies. The impact of these differences are to a large extent unknown, can be difficult to decipher, and may not always be properly considered. Furthermore, the ideal antibody properties for efficacy are not well established and can depend on several factors. However, considering the varied approaches in clinical trials, there is a general optimism that at least some of these trials may provide functional benefits to patients suffering of various tauopathies.
PMID: 32360477 [PubMed - as supplied by publisher]
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Sandusky-Beltran LA, Sigurdsson EM Tags: Neuropharmacology Source Type: research
More News: Alzheimer's | Brain | Clinical Trials | Dementia | Drugs & Pharmacology | Immunotherapy | Lessons | Neurology | Pathology